The value of Granzyme B PET/CT imaging for patients with non-small cell lung cancer

Status

Recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2200062089

Enrollment

Unknown

Registered

2022-07-21

Start date

2022-07-21

Completion date

Unknown

Last updated

2023-04-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung cancer

Interventions

Gold Standard:1. Medical history

2. Radiology

3. Pathology.

Index test:68Ga-GSI PET/CT

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Patients with pathologically confirmed lung cancer; 2. Patients with advanced lung cancer or recurrence or metastasis after treatment; 3. Lung cancer patients treated with neoadjuvant immunotherapy.

Exclusion criteria

Exclusion criteria: 1. Patients are unwilling to fullfill 68GA-GSI or 18F-FDG PET/CT imaging; 2. Patient has a history of another malignant tumors.

Design outcomes

Primary

Measure	Time frame
SUVmax (Standardized Uptake Value max);	—

Secondary

Measure	Time frame
Tumor-to-background ratios;	—

Countries

China

Contacts

Public ContactShaoli Song

Fudan University Shanghai Cancer Center

shaoli-song@163.com+86 13816608573

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Aug 16, 2026